• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

促尿酸排泄药物研究进展

尧贵林, 王海勇, 陆涛

尧贵林, 王海勇, 陆涛. 促尿酸排泄药物研究进展[J]. 中国药科大学学报, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
引用本文: 尧贵林, 王海勇, 陆涛. 促尿酸排泄药物研究进展[J]. 中国药科大学学报, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
Citation: YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417

促尿酸排泄药物研究进展

Advances of the uricosuric drugs

  • 摘要: 促尿酸排泄是治疗痛风和高尿酸血症的重要途径,其机制主要包括两个方面:一是抑制肾小管尿酸转运体对尿酸盐的转运,减少尿酸重吸收,促进排泄;另一方面是促进尿酸氧化分解成溶解性更好的尿囊素,提高尿酸排泄量。本文对促尿酸排泄药物作用机制及其研究进展进行综述,为该类药物研究与开发提供参考。
    Abstract: Promoting uric acid excretion is an important approach for the treatment of gout and hyperuricemia. There are two main approaches included in the mechanism: one is inhibiting the function of renal tubular uric acid transporter to reduce the absorption of uric acid, and promoting excretion; the other is using uricase to catalyze the oxidation of uric acid to a more water-soluble allantoin that can also increase excretion. The mechanisms and progress of the uricosuric drugs are reviewed in this paper, providing reference for the further research and development.
  • [1] Choi HK,Mount DB,Reginato AM,et al.Pathogenesis of gout [J].Ann Intern Med,2005,143(7):499-516.
    [2] Kang DH,Nakagawa T,Feng L,et al.A role for uric acid in the progression of renal disease [J].J Am Soc Nephrol,2002,13(12):2888-2897.
    [3] De Lau LM,Koudstaal PJ,Hofman A,et al.Serum uric acid levels and the risk of Parkinson disease [J].Ann Neurol,2005,58(5):797-800.
    [4] Rizwan AN,Burckhardt G.Organic anion transporters of the SLC22 family:biopharmaceutical,physiological,and pathological roles [J].Pharm Res,2007,24(3):450-470.
    [5] Anzai N,Jutabha P,Kanai Y,et al.Integrated physiology of proximal tubular organic anion transport [J].Curr Opin Nephrol Hypertens,2005,14(5):472-479.
    [6] Miyazaki H,Anzai N,Ekaratanawong S,et al.Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins [J].J Am Soc Nephrol,2005,16(12):3498-3506.
    [7] Burns CM,Wortmann RL.Gout therapeutics:new drugs for an old disease [J].Lancet,2011,377(9760):165-177.
    [8] Matsuo H,Nakayama A,Sakiyama M,et al.ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload [J].Sci Rep,2014,4:3755.
    [9] Li S,Sanna S,Maschio A,et al.The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts [J].PLoS Genet,2007,3(11):2156-2162.
    [10] Preitner F,Bonny O,Laverrière A,et al.Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy [J].Proc Natl Acad Sci U S A,2009,106(36):15501-15506.
    [11] Watanabe S,Kanellis J,Nakagawa T,et al.Reducing uric acid as a means to prevent cardiovascular and renal disease [J].Expert Opin Ther Pat,2002,12(2):193-199.
    [12] Fleischmann R,Kerr B,Yeh LT,et al.Pharmacodynamic,pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia [J].Rheumatology,2014,53(12):2167-2174.
    [13] Tan PK, Hyndman D, Liu S, et al. Lesinurad(RDEA594),a novel investigational uricosuric agent for hyperuricemia and gout,blocks transport of uric acid induced by hydrochlorothiazide[J].Ann Rheum Dis,2011,70(Suppl 3):187.
    [14] Miner JN, Tan P. RDEA3170, a novel, high affinity URAT1 inhibitor binds to a central domain within URAT1 [J].Ann Rheum Dis,2013,71(Suppl 3):446 [2015-07-14] .doi: 10.1136/annrheumdis-2012-eular.2846.
    [15] Ahn S,Horiba N,Ohtomo S,et al.The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout[J].Ann Rheum Dis,2013,72(Suppl 3):A704 [2015-07-14] .doi: 10.1136/annrheumdis-2013-eular.2081.
    [16] Lavan BE,Mcwherter C,Choi YJ.Arhalofenate,a novel uricosuric agent,is an inhibitor of human URIC acid transporters [J].Ann Rheum Dis,2013,71(Suppl 3):450-451.
    [17] Steinberg A,Vince B,Choi YJ,et al.A Study to evaluate the pharmacodynamics,pharmacokinetics and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout [J].Ann Rheum Dis,2015,74(Suppl 2):543-544.
    [18] Noveck RJ,Wang ZY,Forathoefel A,et al.Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout [J].Arthitis Rheum,2012,64(Suppl 10):818.
    [19] Mandal A,Emerling D,Serafini T,et al.Tranilast inhibits urate transport mediated by URAT1 and GLUT9 [J].Arthritis Rheum,2010,62(Suppl 10):164.
    [20] Sundy JS,Kitt M,Griffith SG,et al.The combination of tranilast with allopurinol results in enhanced urate-lowering [J].Arthritis Rheum,2010,62(Suppl 10):S67-S68.
    [21] Warrell RP,Klukovits A,Barnes K,et al.Novel bifunctional inhibitors of xanthine oxidase and URAT1 induce profound hypouricemiain human subjects [J].Ann Rheum Dis,2014,73(Suppl 2):786.
    [22] Richette P,Briere C,Honene CV,et al.Rasburicase for tophaceous gout not treatable with allopurinol:an exploratory study [J].J Rheumatol,2007,34(10):2093-2098.
    [23] Sundy JS,Ganson NJ,Kelly SJ,et al.Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout [J].Arthritis Rheum,2007,56(3):1021-1028.
计量
  • 文章访问数:  1004
  • HTML全文浏览量:  3
  • PDF下载量:  3988
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-08-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭